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1tatins in Patients
ith Chronic Kidney Disease:
Double-Edged Sword?
n their recent article, Harper and Jacobson (1) reviewed the
anagement of dyslipidemia in chronic kidney disease (CKD) and
iscussed the potential renoprotective effects of statins. We would
ike to quote further data regarding the renoprotective effects of
tatins, but also refer to existing pre-clinical evidence suggesting
otential harmful effects of statins in CKD, a perspective that was
argely overlooked by the authors.
A recent meta-analysis in CKD, dialysis, and transplanted
atients concluded that statins modestly reduced proteinuria but
id not affect the rate of decline of glomerular filtration rate (GFR)
2). Similarly, Douglas et al. (3) reported an antiproteinuric effect
f statins, while a contemporary meta-analysis detected a congener
ffect of statins on proteinuria and a decrease in the rate of GFR
eduction by a mean of 1.22 ml/min/year (4). Pravastatin was
roven to be beneficial in retarding the decrease in kidney function
n a subgroup analysis of the CARE (Cholesterol and Recurrent
vents) trial (5), which was consonant with the findings of Fried
t al. (6). However, these meta-analyses should be interpreted with
aution; most of them mix prospective studies with post-hoc
ubstudies of major randomized trials, in others, data are relatively
parse, and in some of them, the results are heterogeneous between
he examined studies.
Importantly, several lines of pre-clinical evidence indicate that
tatins may favor the development of renal fibrosis and, therefore,
ight be harmful in the long-term management of patients with
KD. In that regard, it has been recently demonstrated that statins
re potential stimulators of transforming growth factor (TGF)-
ignaling through decreasing cholesterol levels (7). Cholesterol
ecreases TGF- binding to its receptors ALK5 and TRII, thus
ffectively suppressing TGF- signaling. It is now well established
hat enhanced TGF- signaling is a key pathogenetic mechanism
ontributing to the development of renal fibrosis (8,9). The known
mmunomodulatory effects of statins should also be considered in
he management of CKD patients who are known to be
elatively immunodeficient. Statins may worsen certain infec-
ious diseases that are not uncommon in CKD or dialysis
atients, including human immunodeficiency virus, hepatitis B
irus, and hepatitis C virus infections, by increasing regulatory
cells concentration (10).
Given the absence of prospective randomized controlled studies
hat directly address the role of statins in CKD as well as the
imitations of the aforementioned meta-analyses, use of statins as
enoprotective medications in CKD should be carefully monitored
nd always individualized. Physicians should be well aware of the
otential harmful effects of statins in CKD, which have been
uggested in pre-clinical studies and may emerge when well
esigned prospective studies directly addressing the role of statins
1n CKD are completed. These studies, including the PLANET II
Prospective Evaluation of Proteinuria and Renal Function in
on-Diabetic Patients With Progressive Renal Disease) trial (11),
he LORD (Lipid lowering and Onset of Renal Disease) trial (12),
nd the SHARP (Study of Heart And Renal Protection) trial (13),
ill hopefully elucidate the exact role of statins in CKD and, most
mportantly, define the subgroups of patients that derive benefit or
arm from them.
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